Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 209

1.

Proteasome inhibitors in the treatment of multiple myeloma.

Shah JJ, Orlowski RZ.

Leukemia. 2009 Nov;23(11):1964-79. doi: 10.1038/leu.2009.173. Epub 2009 Sep 10. Review.

PMID:
19741722
[PubMed - indexed for MEDLINE]
2.

Bortezomib and its role in the management of patients with multiple myeloma.

Orlowski RZ.

Expert Rev Anticancer Ther. 2004 Apr;4(2):171-9. Review.

PMID:
15056047
[PubMed - indexed for MEDLINE]
3.

[Proteasome inhibitors].

Saeki Y, Fukunaga K, Tanaka K.

Nihon Rinsho. 2010 Oct;68(10):1818-22. Review. Japanese.

PMID:
20954323
[PubMed - indexed for MEDLINE]
4.

Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.

Bladé J, Cibeira MT, Rosiñol L.

Acta Oncol. 2005;44(5):440-8. Review.

PMID:
16118077
[PubMed - indexed for MEDLINE]
5.

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M.

Br J Haematol. 2012 Sep;158(6):739-48. doi: 10.1111/j.1365-2141.2012.09232.x. Epub 2012 Jul 30.

PMID:
22845873
[PubMed - indexed for MEDLINE]
6.

Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.

Cheriyath V, Jacobs BS, Hussein MA.

Drugs R D. 2007;8(1):1-12. Review.

PMID:
17249845
[PubMed - indexed for MEDLINE]
7.

Proteasome inhibition for treatment of multiple myeloma: clinical update.

Stadtmauer EA.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S10-5. Review.

PMID:
19795531
[PubMed - indexed for MEDLINE]
8.

Proteasome inhibition in multiple myeloma.

Kropff M, Bisping G, Wenning D, Berdel WE, Kienast J.

Eur J Cancer. 2006 Jul;42(11):1623-39. Epub 2006 Jul 3. Review.

PMID:
16820291
[PubMed - indexed for MEDLINE]
9.

Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.

Richardson PG, Hideshima T, Anderson KC.

Cancer Control. 2003 Sep-Oct;10(5):361-9. Review.

PMID:
14581890
[PubMed - indexed for MEDLINE]
Free Article
10.

Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP.

Curr Cancer Drug Targets. 2011 Mar;11(3):239-53. Review.

PMID:
21247388
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ.

Blood. 2007 Nov 1;110(9):3281-90. Epub 2007 Jun 25.

PMID:
17591945
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Role of carfilzomib in the treatment of multiple myeloma.

Khan RZ, Badros A.

Expert Rev Hematol. 2012 Aug;5(4):361-72.

PMID:
22992230
[PubMed - indexed for MEDLINE]
13.

The development of proteasome inhibitors as anticancer drugs.

Adams J.

Cancer Cell. 2004 May;5(5):417-21. Review.

PMID:
15144949
[PubMed - indexed for MEDLINE]
14.

The future of proteasome inhibitors in relapsed/refractory multiple myeloma.

Orlowski RZ.

Oncology (Williston Park). 2011 Nov 15;25 Suppl 2:56-64. Review.

PMID:
25188482
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

New drugs for myeloma.

Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K.

Oncologist. 2007 Jun;12(6):664-89. Review.

PMID:
17602058
[PubMed - indexed for MEDLINE]
Free Article
16.

Proteasome inhibitor bortezomib for the treatment of multiple myeloma.

Cavo M.

Leukemia. 2006 Aug;20(8):1341-52. Epub 2006 Jun 29. Review.

PMID:
16810203
[PubMed - indexed for MEDLINE]
17.

Bortezomib: a review of its use in patients with multiple myeloma.

Curran MP, McKeage K.

Drugs. 2009;69(7):859-88. doi: 10.2165/00003495-200969070-00006. Review.

PMID:
19441872
[PubMed - indexed for MEDLINE]
18.

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.

Richardson PG, Mitsiades C, Ghobrial I, Anderson K.

Curr Opin Oncol. 2006 Nov;18(6):598-608. Review.

PMID:
16988581
[PubMed - indexed for MEDLINE]
19.

Proteasome inhibitor therapy in multiple myeloma.

Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC.

Mol Cancer Ther. 2005 Apr;4(4):686-92. Review.

PMID:
15827343
[PubMed - indexed for MEDLINE]
Free Article
20.

The ubiquitin proteasome pathway from bench to bedside.

Orlowski RZ.

Hematology Am Soc Hematol Educ Program. 2005:220-5.

PMID:
16304384
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk